Pulse afatinib for ERBB2 exon 20 insertion mutated lung adenocarcinomas

Eitemau Tebyg

• EGFR exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas
  gan: Jorge, Susan E., et al.
  Cyhoeddwyd: (2018)
• Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients
  gan: Liu, Zhefeng, et al.
  Cyhoeddwyd: (2018)
• Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib
  gan: Ikeuchi, Tomoyuki, et al.
  Cyhoeddwyd: (2019)
• Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
  gan: Jorge, Susan E., et al.
  Cyhoeddwyd: (2015)
• Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
  gan: Bo Yuan, et al.
  Cyhoeddwyd: (2020-05-01)